- Home
- BIAF vs IMNN Comparison
BIAF vs IMNN Comparison
Compare BIAF & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- IMNN
- Stock Information
- Founded
- BIAF 2014
- IMNN 1982
- Country
- BIAF United States
- IMNN United States
- Employees
- BIAF N/A
- IMNN N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- IMNN Health Care
- Exchange
- BIAF Nasdaq
- IMNN Nasdaq
- Market Cap
- BIAF 12.2M
- IMNN 12.1M
- IPO Year
- BIAF 2022
- IMNN 1985
- Fundamental
- Price
- BIAF $0.21
- IMNN $0.61
- Analyst Decision
- BIAF Hold
- IMNN Strong Buy
- Analyst Count
- BIAF 1
- IMNN 2
- Target Price
- BIAF N/A
- IMNN $15.50
- AVG Volume (30 Days)
- BIAF 799.6K
- IMNN 209.1K
- Earning Date
- BIAF 05-23-2025
- IMNN 05-12-2025
- Dividend Yield
- BIAF N/A
- IMNN N/A
- EPS Growth
- BIAF N/A
- IMNN N/A
- EPS
- BIAF N/A
- IMNN N/A
- Revenue
- BIAF $9,362,022.00
- IMNN N/A
- Revenue This Year
- BIAF N/A
- IMNN N/A
- Revenue Next Year
- BIAF $19.99
- IMNN N/A
- P/E Ratio
- BIAF N/A
- IMNN N/A
- Revenue Growth
- BIAF 269.68
- IMNN N/A
- 52 Week Low
- BIAF $0.16
- IMNN $0.64
- 52 Week High
- BIAF $2.99
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- BIAF 32.86
- IMNN 24.71
- Support Level
- BIAF $0.19
- IMNN $0.60
- Resistance Level
- BIAF $0.24
- IMNN $1.08
- Average True Range (ATR)
- BIAF 0.04
- IMNN 0.08
- MACD
- BIAF -0.02
- IMNN -0.02
- Stochastic Oscillator
- BIAF 13.80
- IMNN 3.12
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).